New study explores drug cocktails for Hard-to-Treat cancers
NCT ID NCT03851614
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two different drug combinations in people with advanced colorectal, pancreatic, or leiomyosarcoma cancers that have not responded to standard treatments. Participants receive either olaparib plus durvalumab or cediranib plus durvalumab. The main goal is to understand how these drugs change immune and genetic markers in the body, not to directly cure the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted chemotherapy pump takes fight directly to pancreatic cancer liver tumors
- Light-Activated therapy targets pancreatic tumors during surgery
- Engineered immune cells take aim at Mesothelin-Positive tumors
- Engineered immune cells and a virus team up against tough cancers
- Oxygen mapping in pancreatic tumors could reveal hidden clues to aggressive cancer
- Zapping nerves with radiation may ease pancreatic cancer pain